🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.380
0.00 (0.00%)
At close: Nov 18, 2026, 4:00 PM EST
1.390
+0.010 (0.72%)
After-hours: Nov 18, 2026, 4:20 PM EST

Inhibikase Therapeutics Earnings Call Transcripts

Fiscal Year 2026

  • The Phase III program is active across 28 countries and 79 sites, with a safety update planned for H1 2027 and PVR data expected mid-2028. Management highlights potential GI tolerability advantages, oral once-daily dosing and longer-term expansion opportunities.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022